Search
SOLACI Congress
HomeFile

File

View Category
Structural heart disease

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity,...
Dr. Carlos Fava -
Learn More
Pharmacology

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular...
Dr. Omar Tupayachi -
Learn More
Coronary disease

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in...
Dr. Omar Tupayachi -
Learn More
Coronary Disease

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated...
Dr. Omar Tupayachi -
Learn More
Structural Heart Disease

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic...
Dr. Carlos Fava -
Learn More
Other

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended...
Dr. Carlos Fava -
Learn More
Structural heart disease

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher...
Dr. Omar Tupayachi -
Learn More
Structural heart disease

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic...
Dr. Andrés Rodríguez -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACC-2025 Congress Second Day Key Studies

Dr. Juan Manuel Pérez - 0
BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Dr. Omar Tupayachi - 0
Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

Dr. Omar Tupayachi - 0
The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

Institutional News

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Uruguay Sessions 2025 | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submission LI SOLACI Regional Sessions – 16° Southern Cone  It is with great pleasure that we hereby invite all young Latin American cardiologists...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy